Avadel Pharmaceuticals Revenue vs. Cash And Equivalents

AVDL Stock  USD 11.06  0.11  0.98%   
Based on Avadel Pharmaceuticals' profitability indicators, Avadel Pharmaceuticals PLC may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Avadel Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
1996-03-31
Previous Quarter
41.5 M
Current Value
50 M
Quarterly Volatility
13.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Avadel Pharmaceuticals' Price To Sales Ratio is quite stable compared to the past year. EV To Sales is expected to rise to 38.40 this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.78. At this time, Avadel Pharmaceuticals' Non Operating Income Net Other is quite stable compared to the past year. Change To Netincome is expected to rise to about 33.2 M this year, although the value of Operating Income is projected to rise to (131 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.650.87
Way Down
Very volatile
For Avadel Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Avadel Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Avadel Pharmaceuticals PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Avadel Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Avadel Pharmaceuticals PLC over time as well as its relative position and ranking within its peers.
  

Avadel Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Trending Equities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
1.036
Quarterly Revenue Growth
26.743
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Avadel Pharmaceuticals Cash And Equivalents vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Avadel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Avadel Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Avadel Pharmaceuticals PLC is rated third in revenue category among its peers. It also is rated third in cash and equivalents category among its peers creating about  3.72  of Cash And Equivalents per Revenue. At this time, Avadel Pharmaceuticals' Total Revenue is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Avadel Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Avadel Revenue vs. Competition

Avadel Pharmaceuticals PLC is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 11.79 Billion. Avadel Pharmaceuticals adds roughly 27.96 Million in revenue claiming only tiny portion of equities under Health Care industry.

Avadel Cash And Equivalents vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Avadel Pharmaceuticals

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
27.96 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Avadel Pharmaceuticals

Cash

 = 

Bank Deposits

+

Liquidities

 = 
104.12 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Avadel Cash And Equivalents Comparison

Avadel Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.

Avadel Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Avadel Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Avadel Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Avadel Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Avadel Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-23.2 M-22 M
Operating Income-137.8 M-131 M
Income Before Tax-160.8 M-152.7 M
Total Other Income Expense Net-22.9 M-21.8 M
Net Loss-160.3 M-152.3 M
Income Tax Expense-501 K-475.9 K
Net Loss-123.7 M-117.5 M
Net Loss-160.3 M-152.3 M
Interest Income14.4 M7.8 M
Non Operating Income Net Other1.9 M2.4 M
Net Interest Income-9.9 M-10.4 M
Change To Netincome31.6 M33.2 M
Net Loss(2.00)(1.90)
Income Quality 0.80  0.59 
Net Income Per E B T 1.00  1.08 

Avadel Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Avadel Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Avadel Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Avadel Pharmaceuticals' important profitability drivers and their relationship over time.

Use Avadel Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Avadel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avadel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Avadel Pharmaceuticals Pair Trading

Avadel Pharmaceuticals PLC Pair Trading Analysis

The ability to find closely correlated positions to Avadel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Avadel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Avadel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Avadel Pharmaceuticals PLC to buy it.
The correlation of Avadel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Avadel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Avadel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Avadel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Avadel Pharmaceuticals position

In addition to having Avadel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Iron Thematic Idea Now

Iron
Iron Theme
Companies involved in production of steel and iron. The Iron theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out Trending Equities.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
To fully project Avadel Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Avadel Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Avadel Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Avadel Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Avadel Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Avadel Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Avadel Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.